Lee A. Henderson, Ph.D., CEO & Chairman, is the founder of VTI. Prior to VTI, he was Director of Molecular Virology at the Guthrie Research Foundation and on the Faculty of Tulane Medical School in the Departments of Pathology and Microbiology and Immunology. He has been the principal investigator on numerous grants from the NIH, NCI, and Department of Defense and was awarded a Postdoctoral Fellowship from the Cancer Research Institute while at the University of Texas Health Science Center in Dallas in the Department of Microbiology.
He has over 40 scientific publications. He has delivered invited lectures, Grand Rounds, served on Institutional Review Boards, and review manuscripts for 9 journals. He has served in the capacity of Director and Medical Advisor to public and private companies. Dr. Henderson currently serves on the Advisory Board to Cornell Advanced Technology Center and the Cornell Agricultural and Life Sciences Council.
Leo B. Kriksunov, Ph.D.
Director of Marketing and Business Development. Prior to joining VTI in August of 2003, Dr. Kriksunov served as Director of Research and Development and New Market Development at Buckbee-Mears Cortland. During his tenure at Buckbee-Mears, Dr. Kriksunov developed novel products and programs in the areas of medical devices, specialty filtration, electronics, fuel cells, novel display technologies, and micro-fluidics. Advanced medical devices components were developed in partnerships with Altea Therapeutics, Becton-Dickinson, Becton Dickinson Technologies, Lifescan, Alza, Cordis, Procter & Gamble, Roche Diagnostics, others. In addition to his expertise in managing R&D; and New Business Development, Dr. Kriksunov also has extensive experience developing Intellectual Property management programs and funding proposals. He has over fifty technical publications.
Kenneth Bartels, Director is an active private investor in both early-stage and listed biotech companies. Mr. Bartels is the founder and President of Paxton Properties Incorporated, a real estate investment firm based in New York City that concentrates on acquiring and managing center city office buildings in the United States and Europe. Mr. Bartels is a director of several other private companies. Earlier in his career, Mr. Bartels was an investment banker at Morgan Stanley & Co. Incorporated, New York and Tokyo, and Citicorp, New York. Mr. Bartels holds an A.B., from Harvard College and an M.B.A., from the Harvard Business School.
Nitin Parekh, Ph.D., Director, is currently Vice President and Director of Business and Technology Development for DSM Fine Chemicals in North America. DSM is a $9B dollar corporation with worldwide operations. Dr. Parekh has executive experience and responsibilities that have included managing project and business groups, licensing, corporate alliances and negotiating acquisitions. He has been active in setting strategic goals for VTI and directing our business development activities.
Peter Sears, the Director, is the latest member of the board of directors. Peter retired as President of SR One, the Venture Capital arm of Smith Kline in 1999. Peter developed SR One from inception and has led the group to invest in numerous successful biotechnology companies including, from inception, Amgen. He serves on the board of several biotech companies. Peter has previously served in several executive positions and as counsel for Smith Kline.